Semaglutide vs Tirzepatide
Medically reviewed by the Rite Aid Health Team · Last updated July 2, 2026
Semaglutide and tirzepatide are the two weekly prescription medicines most people compare for weight loss and blood-sugar control. Both have strong evidence; the real decision usually comes down to expected effect, side effects, coverage, availability, and your medical history.
Talk to a clinician about your options
GLP-1 medicines are prescription treatments. A licensed provider can review your history and help you choose and manage the right option — see peptides for weight loss for the broader picture.
At a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GLP-1 + GIP agonist |
| Brands | Ozempic, Wegovy | Mounjaro, Zepbound |
| Cadence | Weekly injection | Weekly injection |
| FDA status | Approved | Approved |
| Key trial program | STEP 1 | SURPASS-2 / SURMOUNT-1 |
Trial program names are the labels drugmakers and researchers use for groups of related clinical studies. These links point to representative ClinicalTrials.gov records, not every study in each program.
How each works
Semaglutide mimics GLP-1, a gut hormone that curbs appetite and improves blood-sugar control. Tirzepatide adds a second target, GIP, which is part of why its trials have shown larger average weight loss.
Who each suits
Both are prescription medicines managed by a clinician. The choice depends on your health history, response, side effects, insurance, and availability — not a one-size answer.
Can you use them together?
No. They are alternatives, not a stack. A clinician helps you choose one and titrate it safely.
Related
Educational information only. Any GLP-1 treatment should be started and supervised by a licensed clinician.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
In their respective trials, tirzepatide has shown larger average weight loss, but individual response varies. This is a decision to make with a clinician, not from an average.
They are peptide-based medicines, but they are FDA-approved drugs — a different category from the research and compounding-track peptides in this section.